Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast

 Sangamo BioSciences Announces First Quarter 2013 Conference Call and Webcast

PR Newswire

RICHMOND, Calif., May 1, 2013

RICHMOND, Calif., May 1, 2013 /PRNewswire/ --Sangamo BioSciences, Inc.
(Nasdaq: SGMO) today announced that the company will release its first quarter
2013 financial results on Wednesday, May 8, 2013, after the market closes. The
press release will be followed by a conference call at 5:00 p.m. ET, which
will be open to the public via telephone and webcast. During the conference
call, the company will review the financial results and discuss other business


The conference call dial-in numbers are 877-377-7553 for domestic callers and
678-894-3968 for international callers. The passcode for the call is
52754725. Participants may access the live webcast via a link on the Sangamo
BioSciences website in the Investors section under "Events and Presentations" For those unable to listen in at the
designated time, a conference call replay will be available for one week
following the conference call, from approximately 8:00 p.m. ET on May 8, 2013
to 11:59 p.m. ET on May 15, 2013. The conference call replay numbers for
domestic and international callers are 855-859-2056 and 404-537-3406,
respectively. The conference ID number for the replay is 52754725.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel
DNA-binding proteins for therapeutic gene regulation and genome editing. It
has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and
efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS.Sangamo's
other therapeutic programs are focused on monogenic diseases, including
hemophilia and hemoglobinopathies such as sickle cell anemia and
beta-thalassemia, and a program in Parkinson's disease. Sangamo's core
competencies enable the engineering of a class of DNA-binding proteins known
as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that
recognize a specific DNA sequence enables the creation of sequence-specific
ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP
TFs) that can control gene expression and, consequently, cell
function.Sangamo has entered into a strategic collaboration with Shire to
develop therapeutics for hemophilia and other monogenic diseases and has
established strategic partnerships with companies in non-therapeutic
applications of its technology including Dow AgroSciences and Sigma-Aldrich
Corporation. For more information about Sangamo, visit the company's website

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.

Contact: Elizabeth Wolffe, Ph.D., Sangamo BioSciences, Inc., 510-970-6000,
Press spacebar to pause and continue. Press esc to stop.